- |||||||||| otelixizumab (ChAglyCD3) / GSK
Journal: Enzymatic characterization of five thioredoxins and a thioredoxin reductase from Myxococcus xanthus. (Pubmed Central) - Aug 14, 2024 Trxs typically have a CGPC active-site motif; however, M. xanthus Trxs have slightly different active-site sequences, with the exception of Trx4...TrxR reduced oxidized Trx1 as the best substrate, with a kcat/Km value of 0.253 min-1 ?M-1, which was 10-28-fold higher than that of the other Trxs. These results suggest that all Trxs possess reducing activity and that Trx1 may be the most functional in M. xanthus because TrxR most efficiently reduces oxidized Trx1.
- |||||||||| otelixizumab (ChAglyCD3) / GSK
Journal: Trx4, a novel thioredoxin protein, is important for Toxoplasma gondii fitness. (Pubmed Central) - Apr 4, 2024 Combining the TurboID system with CRISPR-Cas9 technique revealed many PV-localized proximity proteins associated with Trx4. These findings suggest a versatile role of Trx4 in mediating the processes that occur in this distinctive intracellular membrane-bound vacuolar compartment.
- |||||||||| Journal: Biotransformation of Polyunsaturated Fatty Acids to Trioxilins by Lipoxygenase from Pleurotus sajor-caju. (Pubmed Central) - Dec 4, 2023
PsLOX efficiently converted 10 mM of AA, EPA, and DHA to 8.7 mM of 13,14,15-TrXB3 (conversion rate: 87%), 7.9 mM of 13,14,15-TrXB4 (79%), and 7.2 mM of 15,16,17-TrXB5 (72%) in 15, 20, and 20 min, respectively, marking the highest conversion rates reported to date. Collectively, our results demonstrate that PsLOX is an efficient TrXs-producing enzyme.
- |||||||||| otelixizumab (ChAglyCD3) / GSK, teplizumab (PRV-031) / Provention Bio
Journal, IO biomarker: Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. (Pubmed Central) - Feb 12, 2022 Recent phase II clinical trials with teplizumab in recent-onset T1D seem encouraging, but benefits associated with the use of anti-CD3 mAb in recent-onset T1D are still controversial. A better patient selection, based on immunological profiles and specific biomarkers, is crucial to improve clinical outcomes in T1D immunotherapies.
- |||||||||| [VIRTUAL] Functional characterization of CD3specific DNA aptamers () - Oct 2, 2021 - Abstract #ESGCT2021ESGCT_423;
More recently, bispecific therapies retargeting the cytotoxic activity of effector T cells by binding to CD3 to tumors expressing tumorassociated antigen have demonstrated striking activity in patients across different cancers (blinatumomab and catumaxomab)...Accordingly, these aptamers did not induce any activation of primary human T lymphocytes nor the internalization of CD3 receptors upon binding, which is of particular interest for the development of inert targeting agents without any immunomodulating properties. All together these lead CD3 aptamers exhibit unique properties and qualify for further preclinical and clinical development of CD3targeting therapeutics.
- |||||||||| Review, Journal: Targeting T cells in inflammatory bowel disease. (Pubmed Central) - Jul 8, 2021
The reinduction of lamina propria T cell apoptosis is a mechanism to modulate T cell survival exploited by cyclosporin A, azathioprine and anti-tumor necrosis factor-α agents, such as infliximab, adalimumab and golimumab. In this article, we review the drugs targeting T cells via surface receptors, via T cell-derived cytokines, via CRAC channels or by inducing apoptosis.
- |||||||||| otelixizumab (ChAglyCD3) / GSK, teplizumab (PRV-031) / Provention Bio, Blincyto (blinatumomab) / Astellas, Amgen
[VIRTUAL] Functional Characterization of CD3-Specific DNA Aptamers () - Apr 30, 2021 - Abstract #ASGCT2021ASGCT_434; More recently, bispecific therapies retargeting the cytotoxic activity of effector T cells by binding to CD3 to tumors expressing tumor-associated antigen have demonstrated striking activity in patients across different cancers (blinatumomab)...Preliminary in vivo biodistribution data will also be presented. All together these lead CD3 aptamers exhibit unique properties and qualify for further preclinical and clinical development of CD3-targeting therapeutics.
- |||||||||| otelixizumab (ChAglyCD3) / GSK
IO biomarker: A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease (clinicaltrials.gov) - Aug 19, 2013 P1, N=30, Terminated, Active, not recruiting --> Terminated; The risk-benefit ratio for patients has changed since we initiated the study, and that the study in its current form cannot be justified Active, not recruiting --> Terminated; Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies.
- |||||||||| otelixizumab (ChAglyCD3) / GSK
Trial completion: Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study (clinicaltrials.gov) - Mar 6, 2013 P1, N=28, Completed, Active, not recruiting --> Terminated; Clinical study in Graves' ophthalmopathy terminated until there is a better understanding of an efficacious dose with Otelixizumab from other clinical studies. Active, not recruiting --> Completed
|